164 related articles for article (PubMed ID: 37958305)
1. Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB-IIIA Non-Small-Cell Lung Cancer Patients in Denmark.
Uldbjerg EM; Ringgaard L; Andersen KK; Frederiksen LE; Jovanovic A; Meldgaard P
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958305
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
3. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
4. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
5.
Muthusamy B; Berktas M; Li J; Thomas DS; Sun P; Taylor A; Pennell NA
Future Oncol; 2024 Jun; ():1-14. PubMed ID: 38916211
[No Abstract] [Full Text] [Related]
6. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark.
Ehrenstein V; Eriksen K; Taylor A; Servidio L; Jakobsen E
Cancer Med; 2023 Jan; 12(1):30-37. PubMed ID: 35719062
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
Wang J; Wu YL; Lu S; Wang Q; Li S; Zhong WZ; Wang Q; Li W; Wang B; Chen J; Cheng Y; Duan H; Li G; Shan L; Liu Y; Liu J; Huang X; Bolanos A; He J
JTO Clin Res Rep; 2024 Feb; 5(2):100621. PubMed ID: 38371194
[TBL] [Abstract][Full Text] [Related]
8. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
11. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
16. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV
J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
Chouaid C; Danson S; Andreas S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Price M; Chirila C; Hollis K; Sweeney C; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():310-316. PubMed ID: 30119925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
